Remove about
article thumbnail

FDA Solicits Feedback on the Use of AI and Machine Learning in Drug Development

Bill of Health

Food and Drug Administration (FDA), in fulfilling its task of ensuring that drugs are safe and effective, has recently turned its attention to the growing use of artificial intelligence (AI) and machine learning (ML) in drug development. By Matthew Chun The U.S.

FDA 261
article thumbnail

VR roundup: FDA clears new device for pain, Stanford says immersive therapeutics can help seniors

Healthcare It News

Previously, on September 25, FDA cleared the VR system for the drug-free, temporary relief of acute anxiety associated with needle procedures, Smileyscope said. The company holds a patent for Procedural Choreography, a proprietary technique that reframes real-world stimuli with positive virtual stimuli.

FDA 223
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

FDA Cybersecurity Requirements for Medical Devices Now in Effect

HIPAA Journal

Food and Drug Administration (FDA) will not authorize their use. trillion omnibus spending bill – The Consolidated Appropriations Act, 2023 – took effect and the FDA now requires all regulatory submissions for medical devices to include information about the cybersecurity measures that have been implemented for the devices.

FDA 101
article thumbnail

Public Health Product Hops

Bill of Health

Regulatory and patent exclusivity periods govern the timing of generic entry, and because market share and revenue is often quickly lost upon market entry of generic drugs, extending market exclusivity for any duration can be extremely profitable. My talk was titled “Legal Approaches to Ensuring Timely Generic Drug Availability.”

article thumbnail

The FDA Ramps Up GMP Inspections

Dot Compliance

Prior to the COVID-19 pandemic, during fiscal year (FY) 2019 (October 1, 2018, through September 30, 2019), the FDA conducted 7,266 GMP inspections of registered drug, device and biologics establishments. Compliance Dashboard, Inspections, FDA, accessed October 3, 2022, [link] cd/inspections.htm ). In its February 2022 report, the U.S.

FDA 52
article thumbnail

Psychedelic Lobbying and Regulatory Capture

Bill of Health

Stigler argued that the government’s main “resource” is the “power to coerce,” and therefore a rational interest group would seek to convince the government to use its coercive power for the group’s own benefit. But the most pertinent lobbying is currently working to shape the FDA’s guidelines for psychedelic therapy.

FDA 135
article thumbnail

Is Preemption the Cure for Healthcare Federalism’s Restrictions on Medication Abortion?

Bill of Health

Food and Drug Administration (FDA) is now top of mind for lawyers, scholars, policymakers, and the public. healthcare system, representing just one example of “healthcare federalism” — the division of power between the federal and state governments in the regulation of health care. After Dobbs , U.S.

FDA 176